| Population 2012
|
9.8 million
|
| |
| | |
| Estimates of TB burden * 2012
|
Number (thousands)
|
Rate
(per 100 000 population)
|
| Mortality (excludes HIV+TB)
|
1.8
|
(0.79–3.2)
|
18
|
(8–32)
|
| Mortality (HIV+TB only)
|
0.85
|
(0.7–1)
|
8.6
|
(7.1–10)
|
| Prevalence (includes HIV+TB)
|
20
|
(10–32)
|
199
|
(106–322)
|
| Incidence (includes HIV+TB)
|
13
|
(11–14)
|
130
|
(114–147)
|
| Incidence (HIV+TB only)
|
2.5
|
(2.2–2.8)
|
25
|
(22–28)
|
| Case detection, all forms (%)
|
54
|
(48–62)
|
|
|
| |
| | |
| TB case notifications 2012
|
|
|
|
|
| New cases
|
|
(%)
|
Retreatment cases
|
(%)
|
| Smear-positive
|
4 075
|
(61)
|
Relapse
|
210
|
(69)
|
| Smear-negative
|
667
|
(10)
|
Treatment after failure
|
48
|
(16)
|
| Smear-unknown / not done
|
79
|
(1)
|
Treatment after default
|
47
|
(15)
|
| Extrapulmonary
|
1 887
|
(28)
|
Other
|
0
|
(0)
|
| Other
|
3
|
(<1)
|
|
|
|
| Total new
|
6 711
|
|
Total retreatment
|
305
|
|
|
|
|
|
|
|
|
| Other (history unknown)
|
0
|
|
|
|
|
| Total new and relapse
|
6 921
|
|
Total cases notified
|
7 016
|
|
| |
| | |
| New cases
|
Smear-positive
|
Smear-negative/ unknown/
not done
|
Extrapulmonary
|
| M:F ratio
|
2.1
|
1.7
|
1.3
|
| Age < 15
|
119
|
41
|
365
|
| | |
| | |
| Laboratories
|
2012
|
| Smear (per 100 000 population)
|
1.7
|
| Culture (per 5 million population)
|
0.5
|
| Drug susceptibility testing (per 5 million population)
|
0
|
| Is second-line drug susceptibility testing available?
|
Yes, outside
country
|
| |
| | |
| Treatment success rate 2011 (%)
|
|
|
|
|
| New smear-positive and/or culture-positive
|
92
|
|
Is rifampicin used
throughout treatment for
new patients?
|
Yes
|
| New smear-negative/extrapulmonary
|
84
|
|
| Retreatment
|
85
|
|
| |
| | |
| TB/HIV 2012
|
Number
|
(%)
|
| TB patients with known HIV status
|
5 734
|
(82)
|
| HIV-positive TB patients
|
1 076
|
(19)
|
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)
|
1 009
|
(94)
|
| HIV-positive TB patients on antiretroviral therapy (ART)
|
588
|
(55)
|
| HIV-positive people screened for TB
|
237
|
|
| HIV-positive people provided with IPT
|
|
|
| | |
| | |
| Estimates of MDR-TB burden 2012*
|
|
New
|
|
Retreatment
|
| % of TB cases with MDR-TB
|
2.5
|
(0.01–5)
|
10
|
(3.5–17)
|
MDR-TB cases among notified pulmonary
TB cases
|
120
|
(0–240)
|
31
|
(11–52)
|
| |
| | |
| Reported cases of MDR-TB 2012
|
New
|
Retreatment
|
Total
|
| Cases tested for MDR-TB
|
1 (<1%)
|
23 (8%)
|
24
|
| Laboratory-confirmed MDR-TB cases
|
1
|
23
|
24
|
| Patients started on MDR-TB treatment
|
|
|
36
|
| |
| | |
| Financing TB control
|
2013
|
| National TB programme budget (US$ millions)
|
|
| % Funded domestically
|
|
| % Funded internationally
|
|
| % Unfunded
|
|
| |
| | |